H. Lundbeck A Logo

H. Lundbeck A

Develops and commercializes innovative therapeutics for brain diseases globally.

HLUN | CO

Overview

Corporate Details

ISIN(s):
DK0061804697 (+5 more)
LEI:
5493006R4KC2OI5D3470
Country:
Denmark
Address:
Ottiliavej 9, 2500 Valby
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

H. Lundbeck A/S is a global pharmaceutical company dedicated exclusively to developing and commercializing innovative treatments for brain diseases. The company's core focus is on neuroscience, engaging in the full value chain of research, development, manufacturing, and sales of therapeutics for psychiatric and neurological disorders. Its portfolio addresses a variety of conditions, including depression, migraine, and rare epilepsies. With a mission to advance brain health, Lundbeck markets its specialized products in numerous countries worldwide, managing operations from initial research to patient delivery.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-14 14:51
Regulatory Filings
English 96.8 KB
2025-11-14 12:45
M&A Activity
English 25.3 KB
2025-11-14 12:45
Regulatory Filings
English 96.8 KB
2025-11-11 15:22
Regulatory Filings
English 116.4 KB
2025-11-11 15:22
Earnings Release
English 24.6 KB
2025-09-20 08:00
Regulatory Filings
English 146.2 KB
2025-09-20 08:00
Legal Proceedings Report
English 30.0 KB
2025-08-13 18:41
Interim / Quarterly Report
English 1.0 MB
2025-08-13 18:41
Earnings Release
English 32.1 KB
2025-08-13 18:35
Earnings Release
English 24.2 KB
2025-08-13 18:35
Earnings Release
English 129.5 KB
2025-02-21 13:27
Director's Dealing
English 124.1 KB
2025-02-21 13:27
Director's Dealing
English 29.9 KB
2025-02-05 16:40
Director's Dealing
English 134.1 KB
2025-02-05 16:40
Director's Dealing
English 96.6 KB

Automate Your Workflow. Get a real-time feed of all H. Lundbeck A filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for H. Lundbeck A

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for H. Lundbeck A via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Bone Biologics Corp Logo
Developing a protein-based bone graft for targeted bone regeneration in spinal fusion.
United States of America
BBLG
Bonyf N.V. Logo
Develops patented oral, dental, and dermatological care products for consumers and professionals.
Belgium
MLBON
Boryung Corporation Logo
South Korea
003850
Bosnalijek d.d. Sarajevo Logo
Global manufacturer of drugs for digestive, metabolic, and cardiovascular health.
Bosnia and Herzegovina
BSNL
Boule Diagnostics Logo
Global provider of complete hematology systems for human and veterinary diagnostics.
Sweden
BOUL
Boundless Bio, Inc. Logo
Developing ecDNA-directed therapies for intractable oncogene amplified cancers.
United States of America
BOLD
BridgeBio Oncology Therapeutics, Inc. Logo
Clinical-stage biopharma creating small molecule drugs for RAS-dependent cancers.
United States of America
BBOT
BridgeBio Pharma, Inc. Logo
Develops transformative medicines for genetic diseases and genetically driven cancers.
United States of America
BBIO
BRIGHT MINDS BIOSCIENCES INC. Logo
Developing next-gen serotonergic drugs for neurological and psychiatric disorders like epilepsy.
United States of America
DRUG
Developing novel cancer immunotherapies, including peptide vaccines and iPS-NKT cell therapies.
Japan
4594

Talk to a Data Expert

Have a question? We'll get back to you promptly.